China Medical System Holdings Limited Stock price

Equities

867

KYG211081248

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
8.22 HKD -34.45% Intraday chart for China Medical System Holdings Limited -33.50% -40.61%

Financials

Sales 2023 8.01B 1.11B 8.68B Sales 2024 * 9.8B 1.36B 10.62B Capitalization 28.4B 3.93B 30.75B
Net income 2023 2.4B 332M 2.6B Net income 2024 * 3.54B 491M 3.84B EV / Sales 2023 3.85 x
Net cash position 2023 * 3.9B 540M 4.23B Net cash position 2024 * 5.42B 750M 5.87B EV / Sales 2024 * 2.34 x
P/E ratio 2023
12.8 x
P/E ratio 2024 *
8.08 x
Employees 5,622
Yield 2023 *
4.3%
Yield 2024 *
4.65%
Free-Float 50.45%
More Fundamentals * Assessed data
Dynamic Chart
China Medical System Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Medical System Holdings Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on About 23 May 2024 CI
China Medical System's Atopic Dermatitis Cream Gets Regulatory Nod for Phase 3 Trial MT
China Medical System Holdings Limited Announces Approval to Conduct A Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Atopic Dermatitis in China CI
China Medical System Obtains Nod For Trials of Two Drugs MT
China Medical System Holdings Limited Announces CMS-D001 Tablets and CMS-D002 Capsules Self-Developed CI
China Medical Gains License to Sell Kidney Disease Drug Across China MT
China Approves Phase 3 Clinical Trial for CMS' Vitiligo Cream MT
China Includes CMS' Four Drugs in National Reimbursement List MT
China Medical System Holdings Limited Announces Approval to Conduct a Phase 3 Clinical Trial Investigating Ruxolitinib Cream in Vitiligo in China CI
Chinese Regulator Approves China Medical System's Drug Appilcation for Methotrexate Injection MT
China Medical System Holdings Limited Announces That on 4 December 2023, the New Drug Application for an Additional Indication of Methotrexate Injection Has Been Accepted by the National Medical Products Administration of China CI
Hangzhou HealSun Biopharm Co., Ltd. announced that it has received CNY 200 million in funding from Shenzhen Kangzhe Pharmaceutical Co., Ltd., Hangzhou Oriental Jiafu Asset Management Co., Ltd., China Medical System Holdings Limited CI
China Medical System Holdings Limited entered into the equity transfer agreement to acquire 15% stake in Hangzhou HealSun Biopharm Co., Ltd. from Lepu Biopharma Co., Ltd. for approximately CNY 130 million. CI
China Medical System, A&B Revise Royalty Caps for Nasal Spray MT
More news
1 day-34.45%
1 week-34.76%
Current month-36.08%
1 month-34.97%
3 months-40.17%
6 months-30.34%
Current year-40.61%
More quotes
1 week
8.22
Extreme 8.22
12.74
1 month
8.22
Extreme 8.22
13.00
Current year
8.22
Extreme 8.22
13.98
1 year
8.22
Extreme 8.22
15.86
3 years
8.22
Extreme 8.22
22.80
5 years
6.14
Extreme 6.14
22.80
10 years
6.14
Extreme 6.14
22.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 94-12-31
Director of Finance/CFO 54 94-12-31
Chief Tech/Sci/R&D Officer 64 99-12-31
Members of the board TitleAgeSince
Chief Operating Officer 57 94-12-31
Director/Board Member 55 21-10-05
Director/Board Member 59 20-03-30
More insiders
Date Price Change Volume
24-03-28 8.22 -34.45% 49 726 134
24-03-27 12.54 +0.16% 3,869,884
24-03-26 12.52 +1.95% 4,346,000
24-03-25 12.28 -0.65% 2,399,000
24-03-22 12.36 -1.90% 2,654,500

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
China Medical System Holdings Ltd is a China-based investment holding company principally engaged in the production of medicines, as well as marketing, promotion and sales of drugs, through its subsidiaries. The Company's products include Plendil, Ursofalk, Augentropfen Stulln Mono Eye Drops, Hirudoid, Atopic Piel Series and Vmonalisa, among others. Its major marketed products cover the cardio-cerebrovascular, gastroenterology, ophthalmology, dermatology and medical aesthetic fields. The Company distributes its products within domestic market and to overseas markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
11.58 CNY
Average target price
16.5 CNY
Spread / Average Target
+42.45%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock China Medical System Holdings Limited - Hong Kong S.E.